We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$821M
AUM Growth
-$848M
Cap. Flow
-$726M
Cap. Flow %
-88.46%
Top 10 Hldgs %
68.05%
Holding
41
New
9
Increased
2
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$44.5M
2
HRTX icon
Heron Therapeutics
HRTX
+$31.3M
3
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$26.5M
4
SWTX
SpringWorks Therapeutics
SWTX
+$25.7M
5
MTEM
Molecular Templates, Inc.
MTEM
+$20.6M

Top Sells

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$123M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$98.2M
3
AKBA icon
Akebia Therapeutics
AKBA
+$95.5M
4
CDNA icon
CareDx
CDNA
+$79.1M
5
CYTK icon
Cytokinetics
CYTK
+$78.9M

Sector Composition

Rank Sector Weight
1 Healthcare 84.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
26
Tango Therapeutics
TNGX
$4.41B
$1.86M 0.23%
+180,000
New +$1.84M
FSDC
27
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$1.12M 0.14%
+100,000
New +$1.07M
AKBA icon
28
Akebia Therapeutics
AKBA
$252M
– –
-7,031,283
Closed -$95.5M
APLS
29
DELISTED
Apellis Pharmaceuticals
APLS
– –
-10,000
Closed -$327K
AUPH icon
30
Aurinia Pharmaceuticals
AUPH
$2.11B
– –
-4,621,325
Closed -$75.1M
CDNA icon
31
CareDx
CDNA
$2.42B
– –
-2,232,612
Closed -$79.1M
CYTK icon
32
Cytokinetics
CYTK
$10.4B
– –
-3,347,232
Closed -$78.9M
KPTI icon
33
Karyopharm Therapeutics
KPTI
$48M
– –
-432,787
Closed -$123M
OVID icon
34
Ovid Therapeutics
OVID
$491M
– –
-2,570,878
Closed -$18.9M
QURE icon
35
uniQure
QURE
$3.22B
– –
-50,000
Closed -$2.25M
SRPT icon
36
Sarepta Therapeutics
SRPT
$1.77B
– –
-425,716
Closed -$68.3M
SILK
37
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-5,000
Closed -$209K
ARAV
38
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-964,456
Closed -$11.2M
HARP
39
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-84,416
Closed -$14M
BLU
40
DELISTED
BELLUS Health Inc.
BLU
– –
-1,922,503
Closed -$19.8M
CCXI
41
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-1,706,426
Closed -$98.2M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Consonance Capital Management held 41 positions worth $821M, down 51% from $1.67B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Consonance Capital Management withdrew a net $726M in Q3 2020, closing 14 positions and reducing 15 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $123M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Protagonist Therapeutics worth $46.3M.

  • Consonance Capital Management's largest Q3 2020 buy was Protagonist Therapeutics: 2,369,709 shares worth $46.3M.
  • Consonance Capital Management added most to Aprea Therapeutics in Q3 2020, an estimated $5.8M increase.
  • Consonance Capital Management's biggest Q3 2020 reduction was Mersana Therapeutics, cutting an estimated $49.1M.
  • Consonance Capital Management fully exited Karyopharm Therapeutics in Q3 2020, selling an estimated $123M.
  • Consonance Capital Management's ten largest holdings make up 68% of its $821M portfolio in Q3 2020.
  • Consonance Capital Management opened 9 new positions and closed 14 in Q3 2020.
  • Consonance Capital Management's portfolio value fell 51% quarter-over-quarter to $821M.

Based on Consonance Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.